Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CA 170

Next Previous
Drug Profile

CA 170

Alternative Names: CA-170

Latest Information Update: 21 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aurigene Discovery Technologies
  • Developer Aurigene Oncology; Curis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Programmed cell death 1 ligand 2 inhibitors; Programmed cell death-1 ligand-1 inhibitors; VISTA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bladder cancer; Non-small cell lung cancer; Renal cancer
  • Phase II Lymphoma; Solid tumours
  • No development reported Mesothelioma

Most Recent Events

  • 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 04 Jan 2023 Phase-III clinical trials in Bladder cancer in Asia (PO), prior to January 2023 (Aurigene Discovery Technologies pipeline, January 2023)
  • 04 Jan 2023 Phase-III clinical trials in Non-small cell lung cancer in Asia (PO), prior to January 2023 (Aurigene Discovery Technologies pipeline, January 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top